pSivida
 | This article needs additional citations for verification. (March 2020) |
| Company type | Public company |
|---|---|
| Nasdaq: PSDV ASX: PVA FWB: PV3 | |
| Industry | Pharmaceuticals |
| Headquarters | , |
Number of locations | 2 |
| Products | Iluvien |
| Website | www |
EyePoint Pharmaceuticals, Inc. (formerly pSivida Corp.) pSivida is a
microelectromechanical systems (MEMS) and nanotechnology
to drug delivery.
pSivida obtained
In June 2004, pSivida acquired full ownership of pSiMedica.[1] In April 2018, pSivida purchased eye products firm Icon Bioscience.[3][4]
See also
- Alimera Sciences, pSvida's partner on Iluvien
References
- ^ a b "PSivida lifts pSiMedica stake to 100%". The Sydney Morning Herald. 2004-06-02. Retrieved 2020-10-29.
- ^ "Nano silicon boosts tumour fight". 2004-06-18. Retrieved 2020-10-29.
- ^ "BRIEF—pSivida to buy eye products firm Icon Bioscience". The Pharma Letter. Retrieved 2018-06-22.
- ^ "BRIEF-pSivida Corp Announces Transformative Acquisition Of Icon Bioscience". Reuters. 2018-03-28. Retrieved 2020-10-29.
External links
- Official website
- "pSivida (PSDV) Enters Two Funded Evaluation Agreements with Leading Pharma". StreetInsider.com. May 12, 2015. Retrieved May 15, 2015.
- Lindon, Hal (May 5, 2014). "UPDATE: pSivida Issues Presentation of Preclinical Data Showing Sustained Release of Avastin Using Tethadur". Benzinga. Retrieved May 15, 2015.
pSivida's Dinesh K. Nadarassan presented a poster entitled "Sustained Release of Bevacizumab (Avastin) from BioSilicon"
- pSivida Mesoporous silicon patent
| Divisions and subsidiaries |
| ||||
|---|---|---|---|---|---|
| Shareholdings and partnerships | |||||
| Products |
| ||||
| Places and vessels |
| ||||
| Predecessors | |||||
| People |
| ||||
 | This United States manufacturing company–related article is a stub. You can help Wikipedia by expanding it. |